Navigation Links
REPEL-CV(TM) Adhesion Barrier Receives Endorsement of Kids With Heart
Date:8/7/2009

ISELIN, N.J., Aug. 7 /PRNewswire-FirstCall/ -- SyntheMed, Inc. (OTC Bulletin Board: SYMD), a biomaterials company engaged in the development and commercialization of anti-adhesion products, announced today that REPEL-CV Bioresorbable Adhesion Barrier has received the endorsement of Kids With Heart National Association for Children's Heart Disorders, Inc. Michelle L. Rintamaki, Director of Kids With Heart, stated, "We want to inform parents of children with congenital heart defects about this new surgical device that reduces the risks associated with adhesions during repeat open-heart surgical procedures."

About Adhesions

Adhesions, or scar tissue, occur after virtually all open-heart surgical procedures, often resulting in the heart becoming attached to the sternum and other surrounding tissue surfaces. The presence of adhesions represents a prevalent and serious complication in secondary surgical procedures, increasing the patient risk, length and cost of the surgical procedure.

About REPEL-CV

REPEL-CV is a bioresorbable adhesion barrier film designed to be placed over the surface of the heart at the conclusion of an open-heart surgical procedure to reduce the extent and severity of adhesions. It was recently approved by the US Food and Drug Administration for use in pediatric patients who undergo staged open-heart surgical procedures.

About Kids With Heart NACHD, Inc.

The organization was formed in 1985 with the main mission of providing support, information, and education to the families of children living with congenital heart defects and to promote public awareness of the issues that these families live with on a day to day basis. It is a 501(c)3 organization entirely supported by volunteers.

About SyntheMed, Inc.

SyntheMed, Inc. is a biomaterials company engaged in the development and commercialization of anti-adhesion products. The company is primarily focused on the commercialization of REPEL-CV(TM) Bioresorbable Adhesion Barrier and the advancement and expansion of product development programs based on its proprietary bioresorbable polymer technologies.

Statements in this press release that are not statements of historical fact, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Reference is made to the company's Annual Report on Form 10-KSB for the year ended December 31, 2008, for a description of these, as well as other, risks and uncertainties.

www.kidswithheart.org


'/>"/>
SOURCE SyntheMed, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SyntheMed to Host Symposium on Adhesions in Cardiac Surgery
2. Cellix Ltd. Launches the First Semi-Automated, High Throughput Cell-Adhesion Assay Platform
3. Cellix Ltd. Launches VenaEC Biochip for Flow-based Cell-adhesion Assays
4. FDA Approves SyntheMeds REPEL-CV(R) Adhesion Barrier for Use in Pediatric Cardiac Surgery
5. Novel Product for the Prevention of Post-Surgical Adhesion Formation Completes Phase I Clinical Study
6. Nanoengineered barrier invented to protect plastic electronics from water degradation
7. Barrier Therapeutics to Merge Into Stiefel Laboratories
8. Study Reveals Greatest Barrier to Green Supply Chain Initiatives
9. Physicists tweak quantum force, reducing barrier to tiny devices
10. GlaxoSmithKline Offers New Purchasing Options to Help Employers Overcome Barriers to Pandemic Stockpiling of Relenza(R)
11. Breaking barriers with nanoscale lasers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)...  The Biodesign Challenge (BDC), a university competition that ... living systems and biotechnology, announced its winning teams at ... New York City . The teams, ... at MoMA,s Celeste Bartos Theater during the daylong summit. ... curator of architecture and design, and Suzanne Lee ...
(Date:6/23/2016)... ... ... STACS DNA Inc., the sample tracking software company, today announced that Dr. ... STACS DNA as a Field Application Specialist. , “I am thrilled that Dr. ... STACS DNA. “In further expanding our capacity as a scientific integrator, Hays brings a ...
(Date:6/23/2016)... Calif. , June 23, 2016  Blueprint Bio, ... biological discoveries to the medical community, has closed its ... Matthew Nunez . "We have received ... with the capital we need to meet our current ... essentially provide us the runway to complete validation on ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... the Pennsylvania Convention Center and will showcase its product’s latest features from June ... be presenting a scientific poster on Disrupting Clinical Trials in The Cloud during ...
Breaking Biology Technology:
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... April 28, 2016 First quarter 2016:   ... 966% compared with the first quarter of 2015 The ... 589.1 M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) ... guidance is unchanged, SEK 7,000-8,500 M. The operating margin ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
Breaking Biology News(10 mins):